BioPharma Clinical Trials
TenNor’s TNP-2092 Shows 100% Treatment Success in Early, Acute PJI Phase IIa Trial
TenNor Therapeutics, a near-commercial-stage biotechnology company, announced positive topline results from a Phase IIa proof-of-concept (POC) trial of rif...
September 14, 2026 | News
Exegenesis Bio, Modalis Partner to Advance CRISPR-Based DMD Therapy MDL-201
Exegenesis Bio and Modalis Therapeutics Corporation (TOKYO: 4883; "Modalis") announced that they have signed a research collaboration and license agr...
September 14, 2026 | News
Gan&Lee Doses First Participant in Phase I Trial of Once-Weekly Oral GLP-1 Candidate GZC8072
Gan&Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan&Lee) announced that the first participant has been dosed in a First-In-Human (FIH...
September 11, 2026 | News
Ascletis Begins US Phase I Trial of Oral Amylin Agonist ASC36 for Obesity
- This trial marks the fourth Phase I peptide study for Ascletis this year. - ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at ste...
September 10, 2026 | News
Alebund Secures US FDA IND Clearance for First-in-Class IgA Nephropathy Therapy AP308
Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, announced that it has recen...
September 10, 2026 | News
Harbour BioMed’s HBM9378 Shows Sustained Asthma Control with Twice-Yearly Dosing Potential
The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. ...
September 10, 2026 | News
Accro, Fosun Pharma Secure China Nod for Phase II/III Trial of AC-201 in Vitiligo
Accro Bioscience (Suzhou) Limited ("Accro") today announced that Shanghai Fosun Pharmaceutical Industrial Development Company Limited ("Fosun Pharma Indust...
September 10, 2026 | News
CelluPro Becomes First Chinese Cell Culture Media Supplier to Secure EXCiPACT GMP Certification
CelluPro, a biotechnology company specializing in serum-free cell culture media and bioprocess solutions, has achieved EXCiPACT™ GMP Certif...
September 09, 2026 | News
HORIEN Secures Thai FDA Class 4 Approvals for Three Regenerative Medical Devices
Market-entry initiative targets qualified Thai distributors across dental, surgical, wound-care, and regenerative medicine channels, while solidifying glob...
September 09, 2026 | News
Clover Biopharmaceuticals Reports Positive Phase II Results for RSV-hMPV-PIV3 Combination Vaccines
-- Positive Phase 2 (Australia) results strengthen potential best-in-class profile of RSV+hMPV±PIV3 combination vaccines, with the potential differe...
September 08, 2026 | News
Rznomics Advances High-Efficiency Circular RNA Production with Engineered STS Technology
Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced a major breakthrough in t...
September 08, 2026 | News
AstraZeneca Secures US FDA Approval for ETCAMAH Combination in Advanced Breast Cancer
Approval based on SERENA-6 Phase III trial results which showed combination reduced the risk of disease progression or death by 56% in patients with an e...
September 08, 2026 | News
Evinova, Lothar Medical Partner to Digitise Respiratory Clinical Trials
Evinova, a global leader in AI-native clinical development technology, announced a strategic partnership with Lothar Medical to help transform the ex...
September 08, 2026 | News
Dimerix Secures A$34M Non-Dilutive Funding to Advance Kidney Disease Pipeline Subheadline:
Dimerix successfully enters into non-dilutive facility agreements to access A$34 million[1] with a syndicate of Australian and U.S. independent lend...
September 07, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
